MedPath

Jiangsu Province Hospital of Traditional Chinese Medicine

Jiangsu Province Hospital of Traditional Chinese Medicine logo
🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.jshtcm.com

Clinical Trials

4

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:2
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (50.0%)
Phase 2
2 (50.0%)

Chinese Medicine Treat for Hypertensive Renal Injury

Phase 2
Conditions
Renal Injury
Hypertension
Interventions
Drug: Qianyangyuyin 20g Granule
Drug: placebo
First Posted Date
2019-09-06
Last Posted Date
2019-09-06
Lead Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Target Recruit Count
520
Registration Number
NCT04078711

Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy

Phase 2
Conditions
Peripheral Neuropathy
Interventions
Drug: FOLFOX regimen
Drug: HD6610 Granule
Drug: HD6610 Granule placebo
First Posted Date
2015-10-29
Last Posted Date
2015-12-02
Lead Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Target Recruit Count
64
Registration Number
NCT02590367
Locations
🇨🇳

Jiangsu Province Hospital of Integrated Chinese and Western Medicine, Nanjing, Jiangsu, China

Electric Acupuncture for ICU-acquired Weakness in Mechanical Ventilation Patients

Not Applicable
Conditions
Multiple Organ Dysfunction Syndrome
Respiratory Failure
Sepsis
First Posted Date
2014-07-30
Last Posted Date
2014-07-30
Lead Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Target Recruit Count
40
Registration Number
NCT02204215
Locations
🇨🇳

Department of Intensive Care Unit, Jiangsu Province Hospital of TCM, Nanjing, Jiangsu, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.